FI3652178T3 - Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä - Google Patents

Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä Download PDF

Info

Publication number
FI3652178T3
FI3652178T3 FIEP18740815.8T FI18740815T FI3652178T3 FI 3652178 T3 FI3652178 T3 FI 3652178T3 FI 18740815 T FI18740815 T FI 18740815T FI 3652178 T3 FI3652178 T3 FI 3652178T3
Authority
FI
Finland
Prior art keywords
group
haloalkyl
alkyl
phenyl
cycloalkyl
Prior art date
Application number
FIEP18740815.8T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Snahel Patel
Gregory Hamilton
Guiling Zhao
Huifen Chen
Blake Daniels
Craig Stivala
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of FI3652178T3 publication Critical patent/FI3652178T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
FIEP18740815.8T 2017-07-14 2018-07-12 Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä FI3652178T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762532767P 2017-07-14 2017-07-14
PCT/EP2018/068998 WO2019012063A1 (en) 2017-07-14 2018-07-12 BICYCLIC KETONIC COMPOUNDS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
FI3652178T3 true FI3652178T3 (fi) 2024-03-19

Family

ID=62916677

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18740815.8T FI3652178T3 (fi) 2017-07-14 2018-07-12 Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä

Country Status (30)

Country Link
US (3) US11098058B2 (OSRAM)
EP (2) EP4397309A3 (OSRAM)
JP (2) JP7258843B2 (OSRAM)
KR (2) KR102664604B1 (OSRAM)
CN (2) CN119613408A (OSRAM)
AR (1) AR112274A1 (OSRAM)
AU (3) AU2018300043B2 (OSRAM)
BR (1) BR112020000771A2 (OSRAM)
CA (2) CA3067944C (OSRAM)
CL (1) CL2020000101A1 (OSRAM)
CO (1) CO2020000134A2 (OSRAM)
CR (1) CR20200002A (OSRAM)
DK (1) DK3652178T3 (OSRAM)
ES (1) ES2973661T3 (OSRAM)
FI (1) FI3652178T3 (OSRAM)
HR (1) HRP20240354T1 (OSRAM)
HU (1) HUE065793T2 (OSRAM)
IL (2) IL294961A (OSRAM)
LT (1) LT3652178T (OSRAM)
MA (1) MA49560B1 (OSRAM)
PE (1) PE20200793A1 (OSRAM)
PH (1) PH12020500105A1 (OSRAM)
PL (1) PL3652178T3 (OSRAM)
PT (1) PT3652178T (OSRAM)
RS (1) RS65308B1 (OSRAM)
SG (1) SG11202000333UA (OSRAM)
SI (1) SI3652178T1 (OSRAM)
TW (1) TWI805595B (OSRAM)
UA (1) UA125448C2 (OSRAM)
WO (1) WO2019012063A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018100070A1 (en) * 2016-12-02 2018-06-07 F. Hoffmann-La Roche Ag Bicyclic amide compounds and methods of use thereof
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
US11072617B2 (en) 2017-10-31 2021-07-27 Genentech, Inc. Bicyclic sulfones and sulfoxides and methods of use thereof
EP3908586B1 (en) 2019-01-11 2022-12-21 F. Hoffmann-La Roche AG Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
JP7677584B2 (ja) * 2020-04-27 2025-05-15 オートタック インコーポレーテッド Ｕｂｒボックスドメインリガンドとしての化合物
JP2024513394A (ja) 2021-04-02 2024-03-25 ジェネンテック， インコーポレイテッド 二環式ケトン化合物を作製するための方法
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途
KR20250012616A (ko) 2022-05-19 2025-01-24 머크 샤프 앤드 돔 엘엘씨 Ripk1 억제제 및 사용 방법
WO2024260932A2 (en) * 2023-06-19 2024-12-26 F. Hoffmann-La Roche Ag Process for the preparation of a chiral pyrrolo triazole alcohol

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
AU8071698A (en) 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003265585B2 (en) 2002-08-26 2008-07-03 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
DE602004016992D1 (de) 2003-05-02 2008-11-20 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
JP2008539220A (ja) 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
JP5808869B2 (ja) 2011-11-03 2015-11-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピペラジン化合物
JP6267193B2 (ja) 2012-05-22 2018-01-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換ジピリジルアミン類及びそれらの使用
CN104918934B (zh) 2013-01-18 2017-12-22 霍夫曼-拉罗奇有限公司 3‑取代的吡唑及其作为dlk抑制剂的用途
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
EP2991977B1 (en) 2013-05-01 2020-07-22 F.Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
EA038235B1 (ru) 2013-05-01 2021-07-28 Ф.Хоффманн-Ля Рош Аг Бигетероарильные соединения и их применения
MX368728B (es) 2013-07-10 2019-10-14 Vertex Pharma Amidas de piperidina fusionadas como moduladores de canales de iones.
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
WO2015144609A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
WO2016128908A1 (en) * 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
EP3268373B1 (en) 2015-03-09 2022-04-27 F. Hoffmann-La Roche AG Tricyclic dlk inhibitors and uses thereof
PE20221048A1 (es) * 2015-07-02 2022-06-30 Hoffmann La Roche Lactamas biciclicas como inhibidores de rip1 cinasa
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
KR102808827B1 (ko) 2016-02-05 2025-05-19 데날리 테라퓨틱스 인크. 수용체-상호작용 단백질 키나제 1의 억제제
WO2018100070A1 (en) 2016-12-02 2018-06-07 F. Hoffmann-La Roche Ag Bicyclic amide compounds and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3566471B1 (en) 2017-01-05 2022-09-28 Microsoft Technology Licensing, LLC Audio simulation in video games comprising indirect propagation paths
CN119613408A (zh) 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
MA50356A (fr) 2017-10-11 2021-04-21 Hoffmann La Roche Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
US11072617B2 (en) 2017-10-31 2021-07-27 Genentech, Inc. Bicyclic sulfones and sulfoxides and methods of use thereof

Also Published As

Publication number Publication date
AR112274A1 (es) 2019-10-09
US11834461B2 (en) 2023-12-05
US20210139504A1 (en) 2021-05-13
CN110914271B (zh) 2024-12-10
IL271981A (en) 2020-02-27
JP2020526549A (ja) 2020-08-31
AU2023203292B2 (en) 2025-01-30
JP2023085449A (ja) 2023-06-20
LT3652178T (lt) 2024-04-10
AU2021204369A1 (en) 2021-07-29
SG11202000333UA (en) 2020-02-27
KR102664604B1 (ko) 2024-05-14
US20240300974A1 (en) 2024-09-12
CA3067944C (en) 2023-03-14
WO2019012063A1 (en) 2019-01-17
ES2973661T3 (es) 2024-06-21
JP7258843B2 (ja) 2023-04-17
MA49560B1 (fr) 2024-05-31
CL2020000101A1 (es) 2020-07-17
KR20240065201A (ko) 2024-05-14
IL294961A (en) 2022-09-01
EP4397309A2 (en) 2024-07-10
PH12020500105A1 (en) 2020-11-09
PL3652178T3 (pl) 2024-05-06
CA3185865A1 (en) 2019-01-17
BR112020000771A2 (pt) 2020-07-14
EP3652178A1 (en) 2020-05-20
AU2018300043B2 (en) 2021-04-01
US11098058B2 (en) 2021-08-24
NZ760749A (en) 2024-08-30
CO2020000134A2 (es) 2020-01-17
MA49560A (fr) 2020-05-20
KR20200030558A (ko) 2020-03-20
TWI805595B (zh) 2023-06-21
AU2018300043A1 (en) 2020-01-16
SI3652178T1 (sl) 2024-05-31
CN110914271A (zh) 2020-03-24
RU2020106375A3 (OSRAM) 2022-03-25
UA125448C2 (uk) 2022-03-09
TW201920149A (zh) 2019-06-01
CN119613408A (zh) 2025-03-14
CA3067944A1 (en) 2019-01-17
DK3652178T3 (da) 2024-03-25
IL271981B (en) 2022-09-01
RU2020106375A (ru) 2021-08-16
EP4397309A3 (en) 2024-09-04
PE20200793A1 (es) 2020-08-10
HUE065793T2 (hu) 2024-06-28
EP3652178B1 (en) 2024-01-24
AU2023203292A1 (en) 2023-06-22
CR20200002A (es) 2020-02-10
HRP20240354T1 (hr) 2024-06-07
JP7734163B2 (ja) 2025-09-04
PT3652178T (pt) 2024-03-18
US20190100530A1 (en) 2019-04-04
RS65308B1 (sr) 2024-04-30

Similar Documents

Publication Publication Date Title
FI3652178T3 (fi) Bisyklisiä ketoniyhdisteitä ja niiden käyttömenetelmiä
HRP20171613T1 (hr) Derivati pirazolopirolidina i njihova primjena u liječenju bolesti
PH12020552263A1 (en) Prophylactic or therapeutic agent for spinal muscular atrophy
TN2020000159A1 (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
FI3728254T3 (fi) Bentsyyliaminosubstituoidut pyridopyrimidinonit ja johdannaiset SOS1-estäjinä
ES2563191T3 (es) Compuestos de triazolona como inhibidores de mPGES-1
IL267275A (en) Small molecule inhibitors of the kinase jak family
SI2509974T1 (en) Pyrazoles derivatives modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
JP2016520118A5 (OSRAM)
WO2014068402A3 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
TN2020000195A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
JP2015529217A5 (OSRAM)
PL3873884T3 (pl) Pochodne 3-(chinolin-8-ylo)-1,4-dihydropirydo[3,4-d]pirymidyno-2,4-dionu jako inhibitory integryny alfa4beta7 do leczenia chorób zapalnych
FI3606519T3 (fi) Ask1:n estäjäyhdisteitä ja niiden käyttötapoja
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
MX383747B (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
IL289834B2 (en) Substituted tricyclic compounds as fgfr inhibitors
IL311677B1 (en) History of bicyclic heterocyclyls as IRAK4 inhibitors
CA2471952A1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
HRP20180341T1 (hr) Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd
ME02486B (me) Sigma ligandi za primjenu u prevenciji 1/ili lijecenju postoperaтivnog bola
AR119339A1 (es) DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E
HK1258718A1 (zh) 控释制剂
JP2018535199A5 (OSRAM)
MX2017014438A (es) Cristales de compuesto azabiciclico.